Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market

Sunshine Biopharma (NASDAQ:SBFM) has launched its generic Amoxicillin in Canada and has begun shipping to pharmacies, offering multiple dosages and strengths.

Rhea-AI Summary

Sunshine Biopharma (NASDAQ:SBFM) has launched its generic Amoxicillin in Canada and has begun shipping to pharmacies, offering multiple dosages and strengths. The move expands the company's portfolio of essential generic antibiotics and supports access to affordable, high-quality treatment for a wide range of bacterial infections.

According to Sunshine Biopharma, global Amoxicillin sales were about $4.9 billion in 2025 and are projected to grow at a 2.9% CAGR to roughly $6.4 billion by 2031. Canada represents approximately 2% of this global market. The company currently markets 60 generic drugs in Canada, with about 12 more launches planned for 2026.

Positive

• Launch of generic Amoxicillin in Canada with shipments to pharmacies already underway
• Amoxicillin global market estimated at $4.9 billion in 2025, projected to reach about $6.4 billion by 2031
• Portfolio scale: 60 generic prescription drugs on the Canadian market with ~12 additional launches planned in 2026

Negative

• None.

Argus Aug 7 session 65 alerts

-12.14% close to close 43.8x rel. volume Open Argus

Details

Market reaction after generic Amoxicillin launch: SBFM -12.14% in the Aug 7 session

+26.3% Peak Tracked

-23.5% Trough Tracked

$4.18M Market Cap

In the Aug 7 session, SBFM declined 12.14%, reflecting a significant negative market reaction. Argus tracked a peak move of +26.3% during that session. Argus tracked a trough of -23.5% from its starting point during tracking. Our momentum scanner triggered 65 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 43.8x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -12.1% in the session following this news. The prior -6.54% 24-hour reaction to ne...

Analysis

The stock dropped -12.1% in the session following this news. The prior -6.54% 24-hour reaction to news_id 1087734 showed that a Canadian generic approval had previously coincided with a decline. Recent history was mixed, creating a sourced risk that launch news may not translate into consistent trading response.

Key Figures

2025 global Amoxicillin sales: $4.9 billion Market CAGR: 2.9% 2031 global market: $6.4 billion +3 more

2025 global Amoxicillin sales

$4.9 billion

Global market sales in 2025

Market CAGR

2.9%

Expected global Amoxicillin market growth

2031 global market

$6.4 billion

Projected global Amoxicillin market by 2031

Canadian market share

2%

Canada’s share of the global Amoxicillin market

Generic drugs marketed

60 drugs

Currently marketed in Canada

Additional scheduled launches

12 drugs

Scheduled for the remainder of 2026

Historical Context

5 past events · Latest: Aug 04

5 events

1. Aug 04

   Canadian drug approval

   24h Move

   +12.0%

   Canadian approval expanded the generic women’s health portfolio

2. Jul 28

   Canadian drug approval

   24h Move

   -6.5%

   Health Canada approved generic ondansetron tablets for Canadian distribution

3. Jul 20

   Research publication

   24h Move

   -3.9%

   Peer-reviewed research reported PLpro inhibitor activity across coronavirus variants

4. Jun 25

   Canadian regulatory approval

   24h Move

   +4.9%

   Canadian approval added generic anastrozole to the company portfolio

5. Jun 01

   Canadian drug approval

   24h Move

   -5.9%

   Canadian approval expanded the generic anticoagulant portfolio

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cagr, penicillin-class antibiotic, mrna-lipid nanoparticle, plpro protease inhibitor

4 terms

cagr financial

"increase at a compounded annual growth rate (CAGR) of 2.9%"

Compound Annual Growth Rate (CAGR) measures the average yearly growth of an investment, revenue, or other metric over a multi-year period as if it had grown at a steady rate each year. Think of it like the constant speed that would take you from the starting value to the ending value over the same time—useful because it smooths out ups and downs and lets investors compare different assets or performance periods on an even footing.

penicillin-class antibiotic medical

"Amoxicillin, a widely prescribed penicillin-class antibiotic"

A penicillin-class antibiotic is a medicine derived from the original penicillin family that kills or stops bacteria by weakening their protective outer layers, and is commonly used to treat a wide range of infections. Investors care because these drugs behave like a company's dependable workhorse product: their clinical effectiveness, patent protection, regulatory approvals, manufacturing capacity and the rise of bacterial resistance directly affect sales, margins and future demand.

mrna-lipid nanoparticle technical

"K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer"

A mRNA-lipid nanoparticle is a microscopic delivery system that encloses messenger RNA (mRNA) inside tiny fat-based (lipid) particles so the fragile genetic instructions can survive in the body and enter target cells. Think of it as a protective envelope and delivery truck that carries a delicate message to a specific address. It matters to investors because it is a core platform for developing vaccines and therapeutics, influencing manufacturing needs, regulatory review, intellectual property, and commercial potential.

plpro protease inhibitor medical

"PLpro protease inhibitor, a small molecule for treatment"

A PLpro protease inhibitor is a drug that blocks the papain-like protease (PLpro), an enzyme some viruses use to cut viral proteins into working parts and to interfere with the host immune response. It matters to investors because these compounds are potential antiviral therapies: progress through research, clinical trials, safety testing and regulatory review can change the commercial outlook and valuation of companies developing them, much like a tool that jams a machine preventing it from running.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Sunshine Biopharma's Amoxicillin now shipping to Canadian pharmacies in multiple dosages and strengths

• Launch expands Sunshine Biopharma's growing portfolio of essential prescription medications

• Global Amoxicillin market projected to reach approximately $6.4 billion by 2031

FORT LAUDERDALE, FL / ACCESS Newswire / August 7, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the launch of its generic Amoxicillin formulation in the Canadian market. This strategic expansion reinforces Sunshine Biopharma's commitment to providing affordable, high-quality antibiotics to patients across Canada.

Amoxicillin, a widely prescribed penicillin-class antibiotic, is used to treat a variety of bacterial infections including ear infections, sinus infections, strep throat, pneumonia, bronchitis, urinary tract infections, skin and soft-tissue infections, and dental infections. Sunshine Biopharma's generic version will be available in multiple dosages and strengths, ensuring broad accessibility for prescribers and pharmacists. Sunshine Biopharma started shipping Amoxicillin to pharmacies this week.

Amoxicillin global sales in 2025 were estimated to be $4.9 billion and are expected to increase at a compounded annual growth rate (CAGR) of 2.9% reaching approximately $6.4 billion by 2031. The major drivers for this market growth include increasing prevalence of bacterial infections worldwide and growing adoption of Amoxicillin in pediatric and adult care. According to IQVIA, OECD, Health Canada, the Canadian market comprises approximately 2% of the global total.

"We are proud to add Amoxicillin to our expanding portfolio of generic antibiotics," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "This launch aligns with our mission to deliver essential medications at competitive prices while maintaining the highest standards of quality and compliance."

About Sunshine BiopharmaInc.

Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.

Safe Harbor Forward-Looking Statements

This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.

For more information, please contact:

Camille Sebaaly, CFO Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sunshine Biopharma (NASDAQ:SBFM) announce about Amoxicillin on August 7, 2026?

Sunshine Biopharma announced the launch of its generic Amoxicillin in Canada and the start of pharmacy shipments. According to Sunshine Biopharma, the product is available in multiple dosages and strengths to support broad use in treating various bacterial infections.

In which market is Sunshine Biopharma’s generic Amoxicillin now available?

Sunshine Biopharma’s generic Amoxicillin is now available in the Canadian prescription drug market, with shipments to pharmacies underway. According to Sunshine Biopharma, the Canadian market accounts for about 2% of global Amoxicillin usage based on IQVIA, OECD, and Health Canada data.

What is the estimated global market size for Amoxicillin mentioned by Sunshine Biopharma (SBFM)?

According to Sunshine Biopharma, global Amoxicillin sales were estimated at $4.9 billion in 2025 and are expected to reach about $6.4 billion by 2031. The company cites a 2.9% compounded annual growth rate for this market over the period.

How does the Amoxicillin launch fit into Sunshine Biopharma’s overall product portfolio?

The Amoxicillin launch adds to Sunshine Biopharma’s expanding portfolio of generic antibiotics in Canada. According to Sunshine Biopharma, the company already markets 60 generic prescription drugs there and plans to introduce about 12 additional drugs during the remainder of 2026.

What medical conditions is Sunshine Biopharma’s generic Amoxicillin intended to treat in Canada?

Sunshine Biopharma’s generic Amoxicillin is intended to treat common bacterial infections such as ear, sinus, throat, lung, urinary tract, skin, soft-tissue, and dental infections. According to Sunshine Biopharma, it is a penicillin-class antibiotic widely prescribed in both pediatric and adult care.

Does Sunshine Biopharma have other drug development programs besides generic Amoxicillin?

Yes. Besides generics like Amoxicillin, Sunshine Biopharma is developing K1.1 mRNA for liver cancer and a PLpro protease inhibitor for SARS coronavirus infections. According to Sunshine Biopharma, these programs complement its commercial portfolio of generic prescription medications in Canada.